Moderna (MRNA) has become a pariah in many portfolios. Between reputational overhangs, political weaponization of its COVID success, and fresh regulatory pressures like the labeling requirement just triggered by Florida, the company has seemingly absorbed wave after wave of bad press.
But that’s the point.
1. The chart says it all: a long descent into pessimism, now basing near long-term support. A wedge of reversal is gradually taking shape.
2. Volume spikes not from hype, but from accumulation—stealth hands.
3. Meanwhile, the same narratives that depressed sentiment (public skepticism, regulatory scrutiny) have largely been priced in.
Here’s what the crowd is missing:
a) Moderna isn’t just a COVID trade. Its mRNA platform is still one of the most potent IP arsenals in biotech.
b) Obesity, flu, RSV, oncology—they're positioning for relevance beyond pandemics.
c) In markets driven by liquidity and narratives, the re-rating doesn’t require universal approval, maybe just less animosity.
I'm holding $50 LEAPS for 2027 just to be safe for $4.33 here.
I don't believe in fairy tales.
However, doubling a stock from a bombed-out base doesn't necessitate a miracle—just narrative fatigue, a favorable trial headline, and perhaps, just possibly, a market that rediscovers optionality.
But that’s the point.
1. The chart says it all: a long descent into pessimism, now basing near long-term support. A wedge of reversal is gradually taking shape.
2. Volume spikes not from hype, but from accumulation—stealth hands.
3. Meanwhile, the same narratives that depressed sentiment (public skepticism, regulatory scrutiny) have largely been priced in.
Here’s what the crowd is missing:
a) Moderna isn’t just a COVID trade. Its mRNA platform is still one of the most potent IP arsenals in biotech.
b) Obesity, flu, RSV, oncology—they're positioning for relevance beyond pandemics.
c) In markets driven by liquidity and narratives, the re-rating doesn’t require universal approval, maybe just less animosity.
I'm holding $50 LEAPS for 2027 just to be safe for $4.33 here.
I don't believe in fairy tales.
However, doubling a stock from a bombed-out base doesn't necessitate a miracle—just narrative fatigue, a favorable trial headline, and perhaps, just possibly, a market that rediscovers optionality.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.